Curium agrees to buy Lantheus (2026)
In August 2026, radiopharmaceutical company Curium struck a deal worth up to $8 billion to acquire Lantheus, a major maker of cardiac and cancer imaging agents. The deal followed GE's own move into radiopharma and signaled a wave of consolidation.
The deal underscored how companies are racing to secure radiopharmaceutical supply and drug pipelines.
It previews the competitive pressure GE now faces from rivals building scale in the same market.
Both deals chase the same prize: control of radiopharmaceutical production and distribution as PET imaging and targeted therapy markets grow.
